Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells. The disclosed aromatic polyamine dimers provide highly efficient drugs for targeting cancer cells with active polyamine transporters.

In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.

In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.

Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.

Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.

The present invention provides iron phosphide nanoparticles in which iron atoms are in a low valence state and which are stable under an atmospheric condition, a production method therefor, and a reduction catalyst. The present invention relates to iron phosphide nanoparticles having peaks at diffraction angles (20.5) of 48.3 and 32.7 in a powder X-ray diffraction measurement using CuK radiation, wherein, when the iron phosphide nanoparticles are measured by X-ray photoelectron spectroscopy (XPS), iron atoms contained therein have a peak in a range of 706.0 to 707.5 eV in an Fe2p.sub.3/2 spectrum.

The present invention provides iron phosphide nanoparticles in which iron atoms are in a low valence state and which are stable under an atmospheric condition, a production method therefor, and a reduction catalyst. The present invention relates to iron phosphide nanoparticles having peaks at diffraction angles (20.5) of 48.3 and 32.7 in a powder X-ray diffraction measurement using CuK radiation, wherein, when the iron phosphide nanoparticles are measured by X-ray photoelectron spectroscopy (XPS), iron atoms contained therein have a peak in a range of 706.0 to 707.5 eV in an Fe2p.sub.3/2 spectrum.

Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.

Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.

The present invention relates to novel chemical compounds of indane-, indene-, azaindane-, and azaindene-amines that act as 5-HT2A receptor agonists. These compounds are designed to offer improved therapeutic profiles for the treatment of a variety of neuropsychiatric, neurological, and neurodegenerative disorders. Also disclosed are methods for the synthesis and pharmaceutical use of these compounds.